Specialty Pharmacy

Lanreotide is first antitumor drug to show statistically significant progression-free survival in patients with gastrointestinal and pancreatic tumors.

The FDA today approved ombitasvir, paritaprevir, and ritonavir tablets copackaged with dasabuvir tablets to treat individuals with chronic hepatitis C virus genotype 1 infection, including patients with cirrhosis.

Olaparib treats women with advanced ovarian cancer associated with defective BRCA genes.

Pharmacists tied medical doctors for second place in Gallup's latest honesty and ethics poll.

Study finds hepatitis C co-infection not related to decreased mental function.

FL118 could be effective in treating late stage cancers.

Avella Specialty Pharmacy announced today that Dr. Eric Sredzinski, Pharm.D. is among a team of researchers that received the 2014 Pharmacy Practice Research Award from the American Society of Health-Systems Pharmacists Research and Education Foundation.

To curb an estimated 6% to 11% increase in Medicare Part D spending, 3 states have already placed limitations on which patients with chronic hepatitis C are candidates for treatment with novel antiviral agents.

Thomas Morrow, MD, chief medical officer at Next IT, discusses hurdles that specialty pharmacies need to overcome.

Acro Pharmaceutical Services annual symposium brings together key players from through the specialty pharmacy landscape.

Specific type of non-steroidal anti-inflammatory drugs can increase heart attack risk for some people.

New guidelines seek to address inconsistency in the approach to treatment.

Researchers pinpoint method to reverse cancer cell resistance to chemotherapy.

The growth rate for pharmacists is 14% by 2022.

How can stakeholders save money on the skyrocketing cost of specialty drugs?

Significant challenges remain due to lack of FDA action on existing biosimilar approval guidelines.

Actor and singer Charles Esten, whose daughter was diagnosed with leukemia when she was two and a half, shares the challenging and painful experiences of battling the disease.

The FDA today approved a new indication for ramucirumab for the treatment of metastatic non-small cell lung cancer.

Merck's anti"PD-1 therapy Keytruda has demonstrated an overall response rate of 18.5% among patients with PD-L1 positive, advanced triple-negative breast cancer, one of the most aggressive forms of breast cancer.

Targeted radiation may also be useful in treating other diseases.

Medication shows promising results in phase 3 study.

Although the proposed USP General Chapter is not anticipated to take effect for at least the next 2 years, an expert panel described how pharmacists can start preparing for the new standards in handling hazardous drugs.

Actimab-A is an alpha radiolabeled antibody in development for newly diagnosed acute myeloid leukemia patients over the age of 60.

The role of pharmacists in HIV care across ambulatory care settings is expanding.

In healthy women, the cons of taking daily low-dose aspirin to prevent heart disease, cancer, and other serious illness outweigh the pros.

Raulo Frear, PharmD, general manager of OmedaRx, discusses effective strategies to ensure patients gain access to high cost specialty medications.

Cimetidine has clinically important benefits in improving colon cancer survival and preclinical evidence shows that this benefit may extend to other types of cancer.

Novo Nordisk announced that its phase 3 study of patients with hemophilia A, who had the highest annualized bleeding rates in its previous study, saw the biggest reduction in bleeding over the duration of treatment using turoctocog alfa.

Agent found to stop growth and spread of prostate cancer with a common chromosomal abnormality.

The FDA today approved of a new indication for Amgen's denosumab for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.